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Abstract
Cyclin D1 (CCND1) protein overexpression and/or the t(11;14)(q13;q32) translocation are the pathognomonic
hallmarks of mantle cell lymphoma (MCL). However, there have been cases that lacked both t(11;14) and cyclin D1
protein but still had a gene expression profile suggesting a diagnosis of MCL. SOX11 expression was detected in
most cyclin D1- negative MCL and can serve as a specific biomarker for the diagnosis of this subset of MCL. Lack of
SOX11 expression in MCL was associated with an indolent subset and favorable prognosis.
Background
Mantle cell lymphoma (MCL) is a distinct subtype of
non-Hodgkin lymphoma [1]. The immunophenotype of
the cells resembles the lymphocytes in the mantle zone
of normal germinal follicles, and is characterized by co-
expression of B-cell antigens (CD19+, CD20+, CD22+,
CD43+, CD79+, surface immunoglobulin sIgM+, sIgD+)
and the T-cell associated marker CD5+. MCL cells stain
strongly for the antiapoptotic protein BCL-2, but are
negative for germinal center markers like CD10 and
BCL-6 [2, 3]. MCL has pathognomonic chromosomal
translocation t(11;14), leading to constitutive cyclin D1
overexpression. Cyclin D1 (CCND1) overexpression has
been detected in 90 % of MCL patients [3]. SOX11 has
been found to be specifically expressed in more than
90 % of MCL cases. It is especially interesting that
SOX11 was found to be 100 % positive in MCL with
negative CCND1/t(11,14) [4]. Recent literature describes
an indolent form of MCL which has longer duration of
survival [5, 6]. Indolent MCL typically has non-nodal
presentation, hypermutated IGVH, lack of genomic
complexity, and absence of SOX11 expression. There-
fore, SOX11 can serve as a biomarker for diagnosis and
prognosis of a subset of MCL.
SOX11
SOX11 is an intronless gene which encodes a member of
the SOX (SRY-related HMG-box) family of transcription
factors. The gene has 8,719 bases, localized on
chromosome 2p25.3 [7, 8]. SOX11 protein has 441
amino acid residues. SOX11 protein serves as a tran-
scription factor with a DNA-binding high-mobility
group (HMG) domain [9, 10].
SOX11 is a neural transcription factor for the develop-
ing central nervous system in the embryo and is in-
volved in neurogenesis, neural cell survival and neurite
outgrowth. It is also involved in the determination of cell
fate, such as sex differentiation, skeletogenesis, and
stemness.
SOX11 mutations and overexpression have been asso-
ciated with autosomal dominant mental retardation,
coffin-siris syndrome, mantle cell lymphoma, and malig-
nant glioma. Sox11 mRNA is significantly more
expressed in gliomas compared with healthy brain tissue,
suggesting that SOX11 might play a role in malignant
transformation and probably cell survival [11].
SOX11 C1 monoclonal antibody was used to detect
the SOX11 expression in MCL using immunofluores-
cence and flow cytometry studies. The gene was de-
tected in all MCL cases studied, including CCND1
negative MCL cases. SOX11 was not detected in one
case of MCL which was diagnosed with t(11,14) and
immunophenotyping. Such data prove that SOX11 is a
useful diagnostic tool for MCL, irrespective of the
CCND1 presence. It can also be detected by flow cytom-
etry. SOX11 expression can help distinguish MCL from
other B cell lymphomas like chronic lymphoid leukemia
(CLL) as most of them do not stain for SOX11 [12, 13].
However, SOX11 expression detected by immunohisto-
chemistry can be limited by the monoclonal antibodies
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used. A more specific antibody, MRQ-58, was shown to
be able to overcome the problem [14].
SOX11 as a biomarker for cyclin D1-negative MCL
It remains elusive for definitive diagnosis of cyclin D1-
negative MCL. In a study of 238 mature B-cell neo-
plasms, the microarray database was re-examined for
SOX11 expression. The samples underwent immunohis-
tochemistry staining for SOX11 protein. There were 12
cases of cyclin D1-negative MCL, 54 cases of conven-
tional MCL, and 209 other lymphoid neoplasms. SOX11
nuclear protein was positive in 50 cases (93 %) of con-
ventional MCL and also in all the 12 cases (100 %) of
cyclin D1-negative cases of MCL [4]. The SOX11 was
also detected in the six cases of lymphoblastic lymph-
omas, in two of eight cases of Burkitt’s lymphoma, and
in two of three T-prolymphocytic leukemias, but SOX11
expression was not detected in the remaining lymphoid
neoplasms. It appears therefore that SOX11 expression
is a highly specific biomarker for cyclin D1- negative
mantle cell lymphoma.
Sensitive and specific RT-qPCR assay was reported
and used in ongoing longitudinal study to evaluate min-
imal residual disease (MRD) in patients with MCL to
display the correlation between treatment response and
load of MRD [3]. One study investigated 69 cases of
lymphomas, including MCL, marginal zone lymphoma,
follicular lymphoma, small lymphocytic lymphoma, Bur-
kitt lymphoma, plasma cell myeloma and benign lymph
nodes. All of these samples underwent immunostains for
SOX11. 100 % of the 13 cases of MCL was positive for
SOX11 and the rest of the cases were negative [15].
These data suggested that SOX11 can serve as the gen-
etic signature of most MCL [10, 16, 17].
SOX11 as a biomarker for the prognosis in MCL
It has been reported that SOX11 helps not only in diag-
nosing cyclin D1 negative cases, but also helps distin-
guish indolent SOX11 negative MCL from classical
MCL [18]. Indolent MCL has several genes under-
expressed compared to aggressive classical MCL: SOX11
being one of them [5, 6].
In contrast to follicular lymphoma, small lymphocytic
lymphoma and reactive lymphoid tissue, most MCLs
(48/53 patients) in a study expressed SOX11 protein in
the nucleus [19]. This nuclear expression pattern of
SOX11 can therefore serve as a new biomarker for a
subset of MCL. In this study, SOX11 was found to be
only expressed in the cytoplasm in 5/53 MCL cases.
These 5 MCL patients had a shorter survival compared
to the 48 MCL patients with nuclear SOX11 expression.
Hence, the SOX11 expression pattern in MCL may have
a prognostic role.
IN another genomic and gene expression profiling
analysis of MCL case series, 112 cases of MCL were ana-
lyzed for SOX11 expression [6]. Among these 112 cases,
15 cases were negative for SOX11 expression, and were
found to be consistent with indolent MCL which had
significantly better 5 year survival that those positive for
SOX11 expression (78 % SOX11- vs 36 % SOX11+, p =
0.001).
However, in a population based study of 186 cases of
MCL, 13 cases lacked nuclear expression of SOX11, and
had shorter overall survival. Therefore, SOX11 nuclear
expression may be a predictive prognostic biomarker for
indolent MCL in this study [20].
SOX11 in other B cell malignancies
Another study surveyed SOX 11 expression in different
forms of lymphoid malignancies. The study tested one
hundred and seventy-two specimens by immunostaining
for the SOX11 N and C termini. This series reported
that nuclear SOX11 was strongly positive in most B and
T-lymphoblastic leukemia/lymphomas and half of child-
hood Burkitt’s lymphomas, but only weak SOX11 ex-
pression was seen in hairy cell leukemia. SOX11 was
negative in chronic lymphocytic leukemia/lymphoma,
marginal zone, follicular and diffuse large B-cell lymph-
omas, as well as in cases of myeloma, Hodgkin’s lymph-
omas and mature T-cell and NK/T-cell lymphomas [13].
In a recent study of 60 MCL cases, cyclin D1 positive
monotypic plasma cells and lymphoid cells with plasma-
cytic differentiation were observed in 7 SOX11-negative
but in none of 41 SOX11-positive MCLs (P < 0.001) [21].
There have been suggestions that the presence of hyper-
mutated immunoglobulin heavy chain variable gene
(IGVH) in MCL has been associated with negative or
low expression of SOX11. In a study of MCL specimens
using global gene expression, IGVH-mutated/SOX11-
negative MCL cases were shown to have a profile
enriched in memory B cells-related signatures [22].
Therefore, these studies suggest that terminal B cell dif-
ferentiation in MCL may be associated with SOX11
negative phenotypes.
Conclusion
SOX11 expression was detected in most cyclin D1-
negative MCL and can serve as a specific biomarker for
the diagnosis of this subset of MCL. Lack of SOX11 ex-
pression was associated with indolent MCL and favor-
able prognosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DL designed the study. DL, MA and RN drafted and revised the manuscript.
All authors read and approved the final manuscript.
Narurkar et al. Biomarker Research  (2016) 4:6 Page 2 of 3
Acknowledgment
This study was partly supported by Henan Cancer Hospital of Zhengzhou
University, Zhengzhou, China.
Received: 8 February 2016 Accepted: 29 February 2016
References
1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of
haematopoietic and lymphoid tissues in 2008: an overview. Pathologica.
2010;102(3):83–7.
2. Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A,
et al. Histopathology, cell proliferation indices and clinical outcome in
304 patients with mantle cell lymphoma (MCL): a clinicopathological
study from the European MCL Network. Br J Haematol.
2005;131(1):29–38.
3. Hamborg KH, Bentzen HH, Grubach L, Hokland P, Nyvold CG. A highly
sensitive and specific qPCR assay for quantification of the biomarker SOX11
in mantle cell lymphoma. Eur J Haematol. 2012;89(5):385–94.
4. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, et al. SOX11
expression is highly specific for mantle cell lymphoma and identifies the
cyclin D1-negative subtype. Haematologica. 2009;94(11):1555–62.
5. Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica.
2011;96(8):1086–8.
6. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al.
Genomic and gene expression profiling defines indolent forms of mantle
cell lymphoma. Cancer Res. 2010;70(4):1408–18.
7. Jay P, Goze C, Marsollier C, Taviaux S, Hardelin JP, Koopman P, et al. The
human SOX11 gene: cloning, chromosomal assignment and tissue
expression. Genomics. 1995;29(2):541–5.
8. Azuma T, Ao S, Saito Y, Yano K, Seki N, Wakao H, et al. Human SOX11, an
upregulated gene during the neural differentiation, has a long 3’
untranslated region. DNA Res. 1999;6(5):357–60.
9. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic
Acids Res. 1999;27(6):1409–20.
10. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression
of the non B-cell lineage Sox11 transcription factor identifies mantle cell
lymphoma. Blood. 2008;111(2):800–5.
11. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, et al.
Highly specific overexpression of the transcription factor SOX11 in human
malignant gliomas. Oncol Rep. 2005;13(1):139–44.
12. Nordstrom L, Andreasson U, Jerkeman M, Dictor M, Borrebaeck C, Ek S.
Expanded clinical and experimental use of SOX11 - using a monoclonal
antibody. BMC Cancer. 2012;12:269.
13. Dictor M, Ek S, Sundberg M, Warenholt J, Gyorgy C, Sernbo S, et al. Strong
lymphoid nuclear expression of SOX11 transcription factor defines
lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma.
Haematologica. 2009;94(11):1563–8.
14. Lord M, Wasik AM, Christensson B, Sander B. The utility of mRNA analysis in
defining SOX11 expression levels in mantle cell lymphoma and reactive
lymph nodes. Haematologica. 2015;100(9):e369–72.
15. Zhang YH, Liu J, Dawlett M, Guo M, Sun X, Gong Y. The role of SOX11
immunostaining in confirming the diagnosis of mantle cell lymphoma on
fine-needle aspiration samples. Cancer Cytopathol. 2014;122(12):892–7.
16. Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell
lymphomas express a distinct genetic signature affecting lymphocyte
trafficking and growth regulation as compared with subpopulations of
normal human B cells. Cancer Res. 2002;62(15):4398–405.
17. Sara E, Borrebaeck CA. Parallel gene expression profiling of mantle cell
lymphoma - how do we transform ‘omics data into clinical practice. Curr
Genomics. 2007;8(3):171–9.
18. Kuci VNL, Jerkeman M, Ek S. Emerging role of SOX11 in Mantle Cell
Lymphoma. Blood Lymphatic Cancer. 2015;5:35–42.
19. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B,
et al. The subcellular Sox11 distribution pattern identifies subsets of
mantle cell lymphoma: correlation to overall survival. Br J Haematol.
2008;143(2):248–52.
20. Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B,
Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort
of mantle cell lymphoma. Blood. 2012;119(18):4215–23.
21. Ribera-Cortada I, Martinez D, Amador V, Royo C, Navarro A, Bea S, et al.
Plasma cell and terminal B-cell differentiation in mantle cell lymphoma
mainly occur in the SOX11-negative subtype. Mod Pathol.
2015;28(11):1435–47.
22. Palomero J, Vegliante MC, Eguileor A, Rodriguez ML, Balsas P, Martinez D,
Campo E, Amador V. SOX11 defines two different subtypes of mantle cell
lymphoma through transcriptional regulation of BCL6. Leukemia 2016, 30:
doi:10.1038/leu.2015.1355.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Narurkar et al. Biomarker Research  (2016) 4:6 Page 3 of 3
